Archive for the ‘diabetologia’ Category
A journal has retracted a paper by a leading diabetes researcher — who has also issued three corrections — after questions about her research were raised on PubPeer.
The ongoing comments have led Maedler to carefully look through her original data, according to a statement she emailed us: Read the rest of this entry »
Earlier this year, authors retracted a meeting abstract about a diabetes drug, following the revelation that the biotech that funded the trial committed misconduct.
The retraction was initiated by corresponding author Itamar Raz, at Hadassah Medical Center in Israel. The journal didn’t receive a response from any co-authors who were affiliated with the biotech company, Andromeda, so they were not included in the retraction process.
A few months after Hyperion Therapeutics acquired Andromeda’s diabetes drug DiaPep277, Hyperion announced it had evidence that some employees of Andromeda had “engaged in serious misconduct,” such as using un-blinded data and manipulating the analyses. Two relevant studies on the drug, designed to block the immune response that leads to type 1 diabetes, were retracted last year.
Here’s the retraction note for the abstract “Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis,’” published in the May issue of the journal:
The abstract, “Reduced syntaxin-5 in skeletal muscle of patients with type 2 diabetes is linked to increased diacylglycerol, activation of PKCtheta and impaired insulin signalling,” was presented at the annual meeting of the European Association of the Study of Diabetes. The first author was Kurt Højlund, who now is at the University of Southern Denmark. The second author was Pontus Boström, of the Karolinska Institutet.
A diabetes paper that received quite a bit of media attention when it was published in June 2013 was retracted and reissued to fix data errors shortly after publication.
The paper, which showed a steep decline in mortality rates for diabetics in Ontario, Canada, and the UK between 1996 and 2009, was republished in December 2013, with the same conclusion and the errors corrected.
Another paper in Diabetologia by Yoshiyuki Hattori has been retracted for image duplication, marking the second of his articles in the journal to be pulled for that reason.
The notice for the article, “A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells,” states: Read the rest of this entry »
The authors, led by Yoshiyuki Hattori, of Dokkyo University School of Medicine in Mibu (
whose motto, by the way, is “where character is developed through learning” a reader points out that we had the wrong Dokkyo initially), published the same figure twice, and in the same year, in the Journal of Cardiovascular Pharmacology and Biochimica et Biophysica Acta.